DE10299005I2 - Verwendung von 1-Beta-D-ribofuranosyl-1,2,4-triazol-3-carboxamid(Ribavirin) zur Herstellung eines Medikaments für die Behandlung von Arboviren. - Google Patents

Verwendung von 1-Beta-D-ribofuranosyl-1,2,4-triazol-3-carboxamid(Ribavirin) zur Herstellung eines Medikaments für die Behandlung von Arboviren.

Info

Publication number
DE10299005I2
DE10299005I2 DE2002199005 DE10299005C DE10299005I2 DE 10299005 I2 DE10299005 I2 DE 10299005I2 DE 2002199005 DE2002199005 DE 2002199005 DE 10299005 C DE10299005 C DE 10299005C DE 10299005 I2 DE10299005 I2 DE 10299005I2
Authority
DE
Germany
Prior art keywords
ribofuranosyl
carboxamide
triazole
arboviruses
ribavirin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2002199005
Other languages
English (en)
Other versions
DE10299005I1 (de
Inventor
Robert Angus Smith
Humberto Fernandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Research and Development
Original Assignee
Ribapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24673430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10299005(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ribapharm Inc filed Critical Ribapharm Inc
Publication of DE10299005I1 publication Critical patent/DE10299005I1/de
Application granted granted Critical
Publication of DE10299005I2 publication Critical patent/DE10299005I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE2002199005 1984-10-29 1985-04-16 Verwendung von 1-Beta-D-ribofuranosyl-1,2,4-triazol-3-carboxamid(Ribavirin) zur Herstellung eines Medikaments für die Behandlung von Arboviren. Active DE10299005I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66625284A 1984-10-29 1984-10-29

Publications (2)

Publication Number Publication Date
DE10299005I1 DE10299005I1 (de) 2002-05-08
DE10299005I2 true DE10299005I2 (de) 2004-07-01

Family

ID=24673430

Family Applications (3)

Application Number Title Priority Date Filing Date
DE2002199005 Active DE10299005I2 (de) 1984-10-29 1985-04-16 Verwendung von 1-Beta-D-ribofuranosyl-1,2,4-triazol-3-carboxamid(Ribavirin) zur Herstellung eines Medikaments für die Behandlung von Arboviren.
DE3588232T Expired - Lifetime DE3588232T2 (de) 1984-10-29 1985-04-16 Verwendung von 1-Beta-D-ribofuranosyl-1,2,4-triazol-3-carboxamid (Ribavirin) zur Herstellung eines Medikaments für die Behandlung von Arboviren
DE198585302644T Pending DE181050T1 (de) 1984-10-29 1985-04-16 1-beta-d-ribofuranosyl-1,2,4-triazol-3-carboxamid fuer die verwendung in medizinischer behandlung von menschen.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE3588232T Expired - Lifetime DE3588232T2 (de) 1984-10-29 1985-04-16 Verwendung von 1-Beta-D-ribofuranosyl-1,2,4-triazol-3-carboxamid (Ribavirin) zur Herstellung eines Medikaments für die Behandlung von Arboviren
DE198585302644T Pending DE181050T1 (de) 1984-10-29 1985-04-16 1-beta-d-ribofuranosyl-1,2,4-triazol-3-carboxamid fuer die verwendung in medizinischer behandlung von menschen.

Country Status (19)

Country Link
EP (3) EP0181050A3 (de)
JP (1) JPH0713019B2 (de)
KR (1) KR860003018A (de)
AT (1) ATE204173T1 (de)
AU (1) AU584333B2 (de)
BE (1) BE902199A (de)
CA (1) CA1261265A (de)
DD (1) DD261094A5 (de)
DE (3) DE10299005I2 (de)
ES (1) ES8704962A1 (de)
FR (1) FR2572286B1 (de)
GB (1) GB2166050B (de)
HK (1) HK1010985A1 (de)
LU (1) LU85854A1 (de)
NL (1) NL300083I1 (de)
NZ (1) NZ212510A (de)
PH (1) PH22534A (de)
PT (1) PT81387B (de)
ZA (1) ZA858237B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0252962B1 (de) * 1985-12-23 1995-08-23 Fred Hutchinson Cancer Research Center Regulierung der retroviralen replikation, infektion und pathogenese
JP2792246B2 (ja) * 1991-01-31 1998-09-03 信越半導体株式会社 単結晶棒クランプ位置決め治具及びこれを用いた単結晶棒クランプ位置決め方法
MXPA01007211A (es) * 1999-01-29 2002-05-06 Icn Pharmaceuticals Modulacion de la respuesta inmune por ribavirina.
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US7132453B2 (en) * 2002-03-15 2006-11-07 Vanderbilt University Method of using prostacyclin to treat respiratory syncytial virus infections
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
EA201692515A1 (ru) 2014-06-23 2017-05-31 Сановель Илач Санайи Ве Тиджарет А.Ш. Новая фармацевтическая композиция на основе софосбувира и рибавирина
EA201692514A1 (ru) 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
EP2959901A1 (de) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische kombinationen aus sofosbuvir und ribavirin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
AR205339A1 (es) * 1973-03-12 1976-04-30 Icn Pharmaceuticals Sintesis de 1,2,4-triazolo-3-carboxamidas utiles como agentes antivirales
AU564876B2 (en) * 1982-03-29 1987-08-27 Liposome Company, Inc., The Stable plurilamellar vesicles

Also Published As

Publication number Publication date
ES8704962A1 (es) 1987-04-16
HK1010985A1 (en) 1999-07-02
JPH0713019B2 (ja) 1995-02-15
JPS61109723A (ja) 1986-05-28
EP0643970A3 (de) 1997-07-09
DE3588232D1 (de) 2001-09-20
EP0643970B1 (de) 2001-08-16
AU584333B2 (en) 1989-05-25
EP0383361A3 (de) 1993-06-16
DD261094A5 (de) 1988-10-19
EP0383361A2 (de) 1990-08-22
PT81387A (en) 1985-11-01
EP0181050A3 (de) 1987-10-21
ZA858237B (en) 1988-02-24
GB2166050A (en) 1986-04-30
CA1261265A (en) 1989-09-26
BE902199A (fr) 1985-07-31
ATE204173T1 (de) 2001-09-15
ES548303A0 (es) 1987-04-16
DE10299005I1 (de) 2002-05-08
EP0643970A2 (de) 1995-03-22
DE181050T1 (de) 1986-12-18
GB2166050B (en) 1989-08-16
FR2572286B1 (fr) 1990-03-23
EP0181050A2 (de) 1986-05-14
LU85854A1 (fr) 1985-12-16
KR860003018A (ko) 1986-05-19
NZ212510A (en) 1989-04-26
FR2572286A1 (fr) 1986-05-02
DE3588232T2 (de) 2002-06-13
GB8509689D0 (en) 1985-05-22
NL300083I1 (nl) 2002-05-01
PT81387B (pt) 1987-11-11
AU4180785A (en) 1986-05-08
PH22534A (en) 1988-10-17

Similar Documents

Publication Publication Date Title
DE69508192T2 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
ATE132747T1 (de) Sprays zur behandlung von infektionen des tractus respiratorius
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
DE3588232D1 (de) Verwendung von 1-Beta-D-ribofuranosyl-1,2,4-triazol-3-carboxamid (Ribavirin) zur Herstellung eines Medikaments für die Behandlung von Arboviren
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69626276T2 (de) Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
ATE67931T1 (de) Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
NO993997L (no) Anvendelse av 9,10-sekokolesta-5,7,10(19)-trien-1-3-diol, eller alfakalsidol
ATE121935T1 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.
DE69529070T2 (de) Verwendung von 5,6-o-benzyliden-l-ascorbinsäure oder deren salze zur herstellung eines medikaments zur behandlung von hiv
DE69619048D1 (de) Verwendung von Oligosacchariden, welche die Adhäsion an Lewis-x Glycolipid hemmen, zur Herstellung eines Medikaments für die Behandlung von Katarakt
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
ATE39843T1 (de) Verwendung von sekundaeren amidverbindungen zur herstellung von arzneimitteln zur behandlung von dermatologischen entzuendungen.
ATE58476T1 (de) Verwendung von doxaminol zur herstellung eines arzneimittels zur behandlung der peripheren arteriellen verschlusskrankheit.
ATE98612T1 (de) Verfahren zur behandlung von einer waesserigen loesung, die insbesondere salpetersaeure und flusssaeure enthaelt.